A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Mirvetuximab Soravtansine
DRUG: Paclitaxel
DRUG: Topotecan
DRUG: Pegylated liposomal doxorubicin

Sponsor

AbbVie

Collaborators

[object Object]
[object Object]